Molecular diagnostics instrument sales in Asia-Pacific set to normalise as vaccination rates rise

Molecular diagnostics instrument sales in Asia-Pacific set to normalise as vaccination rates rise


Molecular diagnostics (MDX) instrument sales in Asia-Pacific (APAC) are expected to normalise in the next few years due to the high installed base, a result of government-mandated instrument purchases. These purchases caused a significant influx of new molecular analyser installations during the initial pandemic-hit years. 

As vaccination rates rise, instances of covid are expected to decline. When this happens, instrument sales are expected to return to pre-covid-19 figures. MDx analysers require substantial capital investments, ranging from the instrument prices and other required ancillary services, such as biosafety supply chain management systems; it is unlikely that the market will replicate the heights achieved during the pandemic.

Clearstate forecasts that the MDx instrument market will contract by ~15-20% per year in most markets as healthcare facilities are likely to prioritise other purchases that were delayed due to covid-19.

For more on the MDx market, download the white paper on After covid-19: the future of molecular diagnostics in Asia-Pacific.

IVD Gateway: IVD Market and Forecasts with Covid-19 Impact

The go-to-source for Covid-19 impact on In-Vitro Diagnostics test demand in 2020 and market recovery trends in 2021 for all 130+ IVD test segments across countries in Asia, Europe and Latin America.